GlassScriptPhysician profile
Lynn Jackson Howie
NPI 1730315102
$14,707.95
in general payments reported to CMS, 2019-2025
32 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,672 · 2021: $30.61 · 2022: $229 · 2024: $39.99 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $170.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Bioscience INC. | $11,183.75 | 2019 | |
| Pfizer INC. | $1,781.96 | 2019-2025 | |
| Novocure INC. | $657.41 | 2019 | |
| Foundation Medicine, INC. | $229.00 | 2022 | |
| Amgen INC. | $96.67 | 2019-2020 | |
| Genentech USA, INC. | $68.61 | 2019-2020 | |
| Genzyme Corporation | $65.27 | 2019-2020 | |
| Glaxosmithkline, LLC. | $58.68 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $53.44 | 2019-2020 | |
| Celgene Corporation | $48.97 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $46.52 | 2019 | |
| Merck Sharp & Dohme LLC | $36.31 | 2019-2020 | |
| Gilead Sciences, INC. | $35.83 | 2019-2021 | |
| Lilly USA, LLC | $29.50 | 2019 | |
| Astellas Pharma US INC | $28.26 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 414 LLC | $27.58 | 2019 | |
| Alexion Pharmaceuticals, INC. | $27.21 | 2019-2020 | |
| Incyte Corporation | $20.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.97 | 2019 | |
| Tesaro, INC. | $19.69 | 2019 | |
| Taiho Oncology, INC. | $19.53 | 2019 | |
| Abbvie INC. | $17.48 | 2019 | |
| Emd Serono, INC. | $16.77 | 2019 | |
| Janssen Biotech, INC. | $16.48 | 2019 | |
| Exelixis INC. | $16.02 | 2019 | |
| Partner Therapeutics, INC. | $14.47 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.56 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.03 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.85 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.84 | 2019 | |
| Seagen INC. | $11.79 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Howie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.